Compass Therapeutics (NASDAQ:CMPX) CAO Purchases $18,400.00 in Stock

by · The Cerbat Gem

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) CAO Neil Lerner purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The shares were purchased at an average cost of $0.92 per share, with a total value of $18,400.00. Following the completion of the purchase, the chief accounting officer owned 420,000 shares in the company, valued at $386,400. This trade represents a 5.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Neil Lerner also recently made the following trade(s):

  • On Thursday, September 24th, Neil Lerner purchased 2,500 shares of Compass Therapeutics stock. The shares were purchased at an average price of $1.14 per share, for a total transaction of $2,850.00.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $0.86 on Monday. The firm has a market capitalization of $154.28 million, a P/E ratio of -2.14 and a beta of 1.02. Compass Therapeutics, Inc. has a 1-year low of $0.83 and a 1-year high of $6.88. The company’s 50-day moving average is $1.98 and its 200 day moving average is $2.71.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Research analysts anticipate that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on CMPX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Guggenheim decreased their target price on Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 23rd. Citizens Jmp lowered their target price on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 23rd. Lifesci Capital cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.21.

Get Our Latest Research Report on Compass Therapeutics

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC bought a new stake in Compass Therapeutics during the 1st quarter valued at $28,000. HB Wealth Management LLC bought a new position in shares of Compass Therapeutics during the 2nd quarter worth $29,000. State of Wyoming bought a new position in shares of Compass Therapeutics during the 2nd quarter worth $31,000. Wealthcare Capital Partners LLC purchased a new position in shares of Compass Therapeutics during the second quarter valued at $43,000. Finally, Walleye Trading LLC purchased a new position in shares of Compass Therapeutics during the second quarter valued at $55,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

(Get Free Report)

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments.

Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB.

Further Reading